Mechanism of action
Phentermine is a sympathomimetic amine structurally related to amphetamine. Its primary mechanism involves stimulation of norepinephrine release from presynaptic vesicles in the hypothalamus, particularly in the lateral hypothalamic feeding center and ventromedial satiety center.
The increased norepinephrine concentration activates adrenergic receptors, leading to appetite suppression. Phentermine may also have minor effects on dopamine and serotonin neurotransmission, though these are less clinically significant than its noradrenergic action.
The drug does not directly cause weight loss; rather, it reduces caloric intake by decreasing hunger and promoting early satiety. Its effectiveness diminishes with continued use due to tolerance development, which is why it is approved only for short-term use.
Phentermine's sympathomimetic activity also produces CNS stimulation and peripheral effects including increased heart rate, blood pressure elevation, and metabolic rate enhancement.
- Phentermine is a Schedule IV sympathomimetic amine anorectic approved for short-term obesity management (a few weeks).
- Mechanism: stimulates norepinephrine release in the hypothalamus, suppressing appetite centrally.
- Contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, and within 14 days of MAO inhibitors.
- Major adverse effects: hypertension, tachycardia, insomnia, dry mouth; rare but serious: primary pulmonary hypertension.
- Tolerance to anorectic effect develops within weeks; do not increase dose—discontinue instead.
- Most serious drug interaction: MAO inhibitors (risk of hypertensive crisis).
- Phentermine is renally excreted unchanged; half-life 19-24 hours allows once-daily dosing.
- Should be part of comprehensive weight loss program (diet, exercise, behavior modification), not monotherapy.
Indications
Phentermine is indicated as a short-term adjunct (typically a few weeks) in the management of exogenous obesity, as part of a comprehensive weight reduction program that includes:
- Caloric restriction
- Exercise
- Behavioral modification
Patient selection criteria
Phentermine is appropriate for patients with:
- BMI ≥30 kg/m² (obese), OR
- BMI ≥27 kg/m² with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
The drug should be reserved for patients in whom non-pharmacologic measures alone have been insufficient.
Fixed-dose combination
Phentermine is also available in a fixed-dose combination with topiramate (phentermine/topiramate) approved for chronic weight management, which has a different risk-benefit profile and longer approved duration of use than phentermine monotherapy.
Off-label uses
Phentermine has no widely accepted off-label uses. Its use is limited to obesity management.
Pharmacokinetics
Absorption
Phentermine is well absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations are reached in approximately 3 to 4 hours.
Distribution
The drug distributes into the CNS, where it exerts its appetite-suppressant effects. It crosses the blood-brain barrier readily due to its lipophilic properties.
Metabolism
Phentermine undergoes limited hepatic metabolism. It is primarily metabolized by CYP3A4 to inactive metabolites, though the extent of metabolism is modest compared to many other drugs.
Elimination
Phentermine is primarily excreted unchanged in the urine. The elimination half-life ranges from 19 to 24 hours, allowing for once-daily dosing. Urinary excretion is pH-dependent: acidic urine increases elimination, while alkaline urine prolongs half-life.
Renal impairment significantly reduces clearance, necessitating dose adjustment or avoidance in severe renal dysfunction.
Adverse effects
Phentermine's adverse effect profile reflects its sympathomimetic activity:
Cardiovascular
- Hypertension (can cause significant elevations)
- Tachycardia and palpitations
- Arrhythmias
- Ischemic events (rare but serious)
- Primary pulmonary hypertension (rare but potentially fatal; risk increases with duration >3 months)
- Valvular heart disease (historically associated with fenfluramine combination, less clear with phentermine alone)
Central nervous system
- Insomnia (very common)
- Restlessness, nervousness, anxiety
- Dizziness, headache
- Tremor
- Euphoria or dysphoria
- Psychotic episodes (rare)
Gastrointestinal
- Dry mouth (xerostomia)
- Constipation or diarrhea
- Unpleasant taste
- Nausea
Other
- Mydriasis and blurred vision
- Urticaria and other hypersensitivity reactions
- Impotence, libido changes
- Dependence and abuse potential (Schedule IV controlled substance)
Tolerance and withdrawal
Tolerance to the anorectic effect typically develops within weeks. Abrupt discontinuation after prolonged use may result in withdrawal symptoms including fatigue, depression, and hyperphagia.
Serious risks
Black box warnings do not currently apply to phentermine monotherapy, but serious cardiovascular events and pulmonary hypertension are recognized risks. The drug should be discontinued if signs of pulmonary hypertension or valvular disease develop.
Contraindications and warnings
Absolute contraindications
- Cardiovascular disease: uncontrolled hypertension, coronary artery disease, heart failure, arrhythmias, stroke, or other significant cardiovascular conditions
- Hyperthyroidism (potentiates sympathomimetic effects)
- Glaucoma (angle-closure type; sympathomimetic effects increase intraocular pressure)
- Agitated states or history of drug abuse
- MAO inhibitor use within 14 days (risk of hypertensive crisis)
- Hypersensitivity to sympathomimetic amines
Warnings and precautions
Pregnancy and lactation: Phentermine is not recommended during pregnancy. Weight loss offers no benefit during pregnancy and may cause fetal harm. It is unknown whether phentermine is excreted in breast milk; breastfeeding is not recommended.
Hypertension: Blood pressure should be monitored regularly. Phentermine can increase blood pressure and should be used with extreme caution, if at all, in patients with even mild hypertension.
Diabetes: Insulin or oral hypoglycemic requirements may decrease with weight loss; monitor glucose closely.
Tolerance: Tolerance to anorectic effects typically develops. Increasing the dose is not recommended when tolerance develops; instead, the drug should be discontinued.
Primary pulmonary hypertension: Rare but serious. Risk appears to increase with use beyond 3 months. Patients should be evaluated if dyspnea or other cardiopulmonary symptoms develop.
Valvular heart disease: Echocardiographic studies are not routinely recommended for phentermine monotherapy, but consider in patients with unexplained symptoms.
Abuse potential: As a Schedule IV controlled substance, phentermine has recognized abuse potential, particularly in individuals with a history of substance use disorders.
Drug interactions
Major interactions
MAO inhibitors: Contraindicated. Concurrent or recent (within 14 days) use can precipitate hypertensive crisis due to excessive norepinephrine accumulation. This is the most serious drug interaction.
Other sympathomimetics: Additive effects increase cardiovascular risks. Avoid concurrent use with decongestants, stimulants, or other anorectics.
SSRIs and serotonergic agents: Theoretical risk of serotonin syndrome when combined with drugs affecting serotonin (e.g., SSRIs, SNRIs, TCAs), though phentermine's serotonergic activity is minimal. Use caution.
Moderate interactions
Antihypertensives: Phentermine may antagonize the effects of antihypertensive medications, reducing their efficacy. Blood pressure monitoring is essential.
Insulin and oral hypoglycemics: Weight loss may enhance insulin sensitivity, reducing requirements for antidiabetic medications. Dose adjustments may be necessary.
Urinary alkalinizing agents (e.g., sodium bicarbonate, acetazolamide): Increase phentermine half-life by reducing renal excretion, potentially enhancing effects and toxicity.
Urinary acidifying agents (e.g., ammonium chloride): Decrease phentermine half-life by increasing renal excretion.
Alcohol: May enhance CNS effects; concurrent use is not recommended.
Pharmacokinetic considerations
Phentermine is a minor CYP3A4 substrate. Strong CYP3A4 inhibitors or inducers may theoretically alter phentermine levels, though clinically significant interactions via this mechanism are uncommon.
Clinical pearls
- Schedule IV controlled substance: Phentermine carries abuse potential and is subject to prescribing restrictions. Documentation of appropriate indication and patient counseling is important.
- Short-term use only: FDA approval is for use "for a few weeks" as part of short-term obesity management. Chronic use beyond 3 months is not recommended for monotherapy due to tolerance and increased risk of pulmonary hypertension.
- Adjunct treatment: Phentermine is an adjunct. Without concurrent caloric restriction, exercise, and behavioral changes, weight loss will be minimal and unsustained.
- Morning dosing preferred: Due to CNS stimulation and insomnia risk, phentermine should be taken in the morning or early afternoon.
- Tolerance expected: Most patients develop tolerance to appetite suppression within 6 to 12 weeks. When this occurs, discontinue rather than escalate dose.
- Blood pressure monitoring: Baseline and periodic monitoring of heart rate and blood pressure is essential. Discontinue if significant elevations occur or if cardiovascular symptoms develop.
- "Phen-fen" history: Phentermine was historically combined with fenfluramine ("phen-fen") until fenfluramine was withdrawn in 1997 due to valvular heart disease and pulmonary hypertension. Phentermine monotherapy has not been definitively linked to valvular disease, but vigilance remains warranted.
- Weight regain after discontinuation: Most patients regain weight after stopping phentermine unless lifestyle modifications are sustained.
- Phentermine/topiramate combination: The fixed-dose combination is approved for chronic use and has broader indications than phentermine monotherapy, but it carries additional risks (e.g., teratogenicity from topiramate, cognitive effects).
- Exam tip: Phentermine questions often test knowledge of contraindications (especially cardiovascular disease and MAO inhibitors), mechanism (norepinephrine release), and recognition that it is a controlled substance with short-term approval only.
Practice questions
1. A 42-year-old woman with a BMI of 33 kg/m² and type 2 diabetes presents for weight management. Her medical history includes well-controlled hypertension on lisinopril. She has tried diet and exercise for 6 months with minimal weight loss. Physical examination shows BP 142/88 mmHg and heart rate 78/min. Which of the following is the most appropriate next step?
2. A 35-year-old man presents to the emergency department with severe headache, palpitations, and diaphoresis. His blood pressure is 210/120 mmHg. He reports starting a new weight-loss medication 3 days ago and has been taking phenelzine for depression for the past 2 months. Which of the following medications was most likely recently started?
3. A 48-year-old woman has been taking phentermine for 8 weeks for obesity management along with diet and exercise. She initially lost 12 pounds but reports that over the past 2 weeks, her appetite has returned and weight loss has plateaued despite adherence to her regimen. Which of the following is the most appropriate management?
Frequently asked questions
How does phentermine work?
Phentermine works by stimulating the release of norepinephrine in the hypothalamus, which suppresses appetite and promotes early satiety. It is a sympathomimetic amine structurally related to amphetamine. The increased norepinephrine activates adrenergic receptors in appetite-regulating centers of the brain, reducing hunger and caloric intake. Phentermine also has mild CNS stimulant effects and increases metabolic rate slightly, though appetite suppression is the primary mechanism for weight loss.
What are the side effects of phentermine?
Common side effects include increased blood pressure, rapid heart rate, palpitations, insomnia, restlessness, dry mouth, and constipation. Serious but rare adverse effects include primary pulmonary hypertension and cardiovascular events such as arrhythmias or myocardial ischemia. Phentermine can also cause nervousness, dizziness, headache, and tremor due to its stimulant properties. As a controlled substance, it carries risk of dependence and withdrawal symptoms (fatigue, depression, increased appetite) after prolonged use.
Is phentermine a controlled substance?
Yes, phentermine is a Schedule IV controlled substance under the Controlled Substances Act due to its abuse potential and stimulant properties. It is structurally similar to amphetamine and can cause psychological dependence. Prescribing is subject to regulatory oversight, and patient history of substance abuse is a contraindication. The controlled status reflects the drug's potential for misuse, though it is considered to have lower abuse potential than Schedule II or III stimulants.
Can phentermine cause high blood pressure?
Yes, phentermine commonly increases blood pressure due to its sympathomimetic effects. It stimulates norepinephrine release, which activates adrenergic receptors in blood vessels, causing vasoconstriction and elevated blood pressure. Phentermine is contraindicated in patients with uncontrolled hypertension or significant cardiovascular disease. Patients taking phentermine require regular blood pressure monitoring, and the drug should be discontinued if hypertension worsens or becomes difficult to control. Even patients with well-controlled hypertension should use phentermine with caution.
Phentermine vs phentermine/topiramate — what is the difference?
Phentermine monotherapy is approved for short-term use (a few weeks) as an adjunct to diet and exercise, while the phentermine/topiramate combination is approved for chronic weight management. The combination leverages topiramate's additional appetite-suppressing and satiety-enhancing effects, providing greater weight loss. However, phentermine/topiramate carries additional risks including teratogenicity (topiramate is a known teratogen requiring pregnancy prevention), cognitive impairment, and metabolic acidosis. Both phentermine alone and the phentermine/topiramate combination are Schedule IV controlled substances.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A08AA01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.